Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

se group and 116.7 hours for patients receiving the placebo. Time to resolution of symptoms for the low dose group were less than for the placebo, but the difference was not statistically significant (P=0.521). Patients in the 600 mg NTZ treatment group also experienced statistically significant reductions in quantitative viral shedding compared to patients receiving the placebo (P=0.0006). Adverse events were similar for the three treatment groups except for a higher rate of mild diarrhea in the 600 mg treatment group (8.1%) compared to the placebo treatment group (3.3%).

About the Phase 2 Clinical Trials

Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another in adults and adolescents age 12 – 65 years, were conducted at a single center in Cajamarca, Peru.  Patients were enrolled based upon symptoms consistent with influenza (fever, at least one respiratory symptom and one constitutional symptom) and randomly assigned to receive treatment with NTZ or placebo in double-blind fashion.  Patients in the pediatric study received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 4 – 11 years) or placebo twice daily for five days as an oral suspension.  Patients enrolled in the study of adults and adolescents received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  Identification of respiratory viruses at baseline was performed by ELISA.  Patients were visited daily by a study nurse to monitor the health of the patients, ensure compliance with the study medication and recording of symptoms in a patient diary, and to collect tissue with nasal secretions, and patients were followed up at study day 7.  The primary efficacy endpoint was time from first dose to alleviation of symptoms (all symptoms absent or mild and remained so for 24 hours).  

One-hundred children, median age 3 years, were enrolled in the pediatric trial (50 per tre
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... announced today development of a novel means of ... nucleic acid, RGBP-248, to liver tumors utilizing a ... in development overcomes previous hurdles with gene silencing ... to be delivered throughout the whole body.  By ...
(Date:8/31/2015)... VIEW, Calif. , Aug. 31, 2015   ... the life sciences team at Google announced today that ... people with type 1 and type 2 diabetes. The ... Google,s expertise in analytics, miniaturized electronics and low power ... diabetes care by developing new tools that bring together ...
(Date:8/31/2015)... 2015  Qualcomm Incorporated (NASDAQ: QCOM ) ... Inc., is collaborating with Davita Healthcare Partners ... powered by Qualcomm Life,s 2net™ Device Connectivity Platform ... care, informed interventions and better management of at-risk ... annual Connect 2015 ecosystem conference taking ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... Mass., Jan. 17, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that a ... Electrophysiology demonstrates the high acute and chronic ... procedure using HeartLight EAS. The study was conducted ...
... Inc. (NYSE Amex: PTN ) announced today ... of non-dilutive funding through the New Jersey Economic Development ... New Jersey net operating losses and research and development ... Palatin Technologies received approximately $637,000 under this program. ...
Cached Medicine Technology:Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 2Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 3Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 4
(Date:8/31/2015)... Chicago, IL (PRWEB) , ... August 31, 2015 ... ... Gynecologic Cancer Awareness Month 2015 in September by sharing the facts about the ... focused on BRCA1 and BRCA2 genetic mutations because of Angelina Jolie Pitt’s decisions ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Move over ... products for men and barbershops are scrambling to meet it. , Reports published this ... for hairstyles and haircare. But the data also reflects that men are getting more ...
(Date:8/31/2015)... ... August 31, 2015 , ... MeYou Health ®, a social well-being ... walking app, Walkadoo , by including an in-app step tracker. , Walkadoo is ... person’s walking habits. Rather than broadly assign every Walkadoo member 10,000 steps a day ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) ... major sports figures who are finding joint pain relief after using their revolutionary Micro-Impact ... tennis player in the world said, “For the first time in over 20 years ...
(Date:8/31/2015)... ... August 31, 2015 , ... According to book reviewer Angie Santangeloon ... Your Life with Cancer is an excellent resource for everyone since one in ... to be helpful in explaining what cancer is in a easy to understand medically ...
Breaking Medicine News(10 mins):Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
... per 1,000 males in the 0-6 age group - has ... Foundation//, to tackle the practice of female foeticide. ... by the Foundation in collaboration with the United Nations Population ... statewide campaign to make people aware of the long-term repercussions ...
... Center in New York say they have identified four genes that ... genes work together. ,Turning off all four genes at ... or metastasise - a study in mice showed. ... planning clinical trials of drugs known to target two of the ...
... patients with untreated sleep apnea are more likely to die than ... ,The study followed 164 patients with heart failure for more than ... had double the death rate of those patients who did not ... death rate was 24% in contrast to 12% for the 113 ...
... Fertility declining among men of north India. And thanks to tight ... of Medical Sciences// (AIIMS), New Delhi. ,A ten-year study ... fertility, reports say. ,The sperm count of a normal ... ml as against 60 million per ml around 30 years ago. ...
... Reports by the Centers for Disease Control and Prevention say there ... Americans//, with a body mass index of 40 or more. ... increased by 50 percent from 2000 to 2005(twice as fast as ... an increase by 24 percent of overweight people (BMI of ...
... the use of insect cells appeared safe and produced ... promises to be an alternative to using embryonated eggs ... preliminary study. ,"All currently licensed influenza ... hen's eggs. There are several well-recognized disadvantages to the ...
Cached Medicine News:Health News:Genes That Spread Breast Cancer Fast Identified 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 3Health News:Denim Lovers Beware, Fertility Could Be in Danger, Says a New Study 2Health News:Experimental Flu Vaccine Appears Promising in Early Tests 2
... The MFERG is available in conjunction ... the UTAS-E3000mf or EPIC-4000 or as a ... MFERG visual electrodiagnostic test uses a software ... monitor to stimulate many areas of the ...
... LKCs Sweep VEP technology is designed for productivity ... in conjunction with doctors from the University of ... over a decade on over 5,000 subjects. All ... be set and stored, or can be preset ...
... the exact enhanced corneal thickness measuring algorithm ... exclusively by the OHTS investigators. The IOP ... The new backlit LCD character displays OD ... and IOP correction calculation and allows easy ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: